Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)

Transplantation

Volumn 73, Issue 6, 2002, Pages 953-959

  Levy, G ^a   Burra, P ^a   Cavallari, A ^a   Duvoux, C ^a   Lake, J ^a   Mayer, A D ^a   Mies, S ^a   Pollard, S G ^a   Varo, E ^a   Villamil, F ^a   Johnston, A ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; TREATMENT FAILURE;

EID: 0037181448     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200203270-00022     Document Type: Article

References (22)

1. Favorable clinical results of Sandimmune-Neoral in malabsorbing liver and heart transplant recipients
2. Sandimmun-Neoral in liver transplantation: A remarkable improvement in long-term immunosuppression
3. Clinical pharmacokinetics of cyclosporin
4. Absorption of cyclosporine Neoral early after liver transplantation: Is it possible to abandon intravenous cyclosporine A application?
5. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation
6. Cyclosporine Neoral in liver transplant recipients
7. The Neoral formulation: Improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients
8. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy
9. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: Results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8)
10. A randomized, prospective, multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group
11. A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation
12. Kidney transplantation: The Halifax experience
13. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients
14. Banff schema for grading liver allograft rejection: Utility in clinical practice
15. Randomized trial of cyclosporine microemulsion (Neoral) versus conventional cyclosporine in liver transplantation
16. Cyclosporine A: Analytical methodology and factors affecting therapeutic drug monitoring
17. A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity
18. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome
19. Advances in diagnosis, prevention and management of hepatic allograft rejection
20. Neoral compared to Sand-immune is associated with a decrease in histologic severity of rejection inpatients undergoing primary liver transplantation
21. Cyclosporine monitoring in patients with renal transplants: Two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure